Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors

Nicotine permeates into the endoplasmic reticulum (ER) where it begins an “inside-out” pathway that leads to addiction. Shivange et al. develop genetically encoded nicotine biosensors and show that nicotine and varenicline equilibrate in the ER within seconds of extracellular application.

[1]  Sparsh Gupta,et al.  Haloperidol-induced parkinsonism is attenuated by varenicline in mice , 2018, Journal of basic and clinical physiology and pharmacology.

[2]  Li I. Zhang,et al.  ED SUM: Signaling by the neurotransmitter acetylcholine is monitored in cells and animals with a sensitive reporter. , 2018, Nature biotechnology.

[3]  A. Nimmerjahn,et al.  Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors , 2018, Science.

[4]  K. O’Malley,et al.  Intracellular GPCRs Play Key Roles in Synaptic Plasticity. , 2018, ACS chemical neuroscience.

[5]  Amol V. Shivange,et al.  Microscopy Using Fluorescent Drug Biosensors for "Inside-Out Pharmacology" , 2018 .

[6]  J. Steyaert,et al.  A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action , 2018, Neuron.

[7]  David Fitzpatrick,et al.  Stability, affinity and chromatic variants of the glutamate sensor iGluSnFR , 2018, Nature Methods.

[8]  W. N. Green,et al.  Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation , 2017, eLife.

[9]  L. Hawk,et al.  Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? , 2017, Journal of smoking cessation.

[10]  Owen Johnson,et al.  Integrating macromolecular X-ray diffraction data with the graphical user interface iMosflm , 2017, Nature Protocols.

[11]  Donghyo Kim,et al.  Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice , 2017, Neuropharmacology.

[12]  H. Lester,et al.  Probing for and Quantifying Agonist Hydrogen Bonds in α6β2 Nicotinic Acetylcholine Receptors. , 2017, Biochemistry.

[13]  Mikhail Drobizhev,et al.  Deciphering the molecular mechanism responsible for GCaMP6m's Ca2+-dependent change in fluorescence , 2017, PloS one.

[14]  C. L. Morales-Pérez,et al.  X-ray structure of the human α4β2 nicotinic receptor , 2016, Nature.

[15]  Charlene H. Kim,et al.  Menthol Alone Upregulates Midbrain nAChRs, Alters nAChR Subtype Stoichiometry, Alters Dopamine Neuron Firing Frequency, and Prevents Nicotine Reward , 2016, The Journal of Neuroscience.

[16]  Charlene H. Kim,et al.  Smoking-Relevant Nicotine Concentration Attenuates the Unfolded Protein Response in Dopaminergic Neurons , 2016, The Journal of Neuroscience.

[17]  B. Hille,et al.  High membrane permeability for melatonin , 2016, The Journal of general physiology.

[18]  M. Marks,et al.  Chronic treatment with varenicline changes expression of four nAChR binding sites in mice , 2015, Neuropharmacology.

[19]  H. Lester,et al.  Inside-out neuropharmacology of nicotinic drugs , 2015, Neuropharmacology.

[20]  P. Faure,et al.  Nicotinic alteration of decision-making , 2015, Neuropharmacology.

[21]  Y. Mineur,et al.  Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states , 2015, Neuropharmacology.

[22]  F. Nees.  The nicotinic cholinergic system function in the human brain , 2015, Neuropharmacology.

[23]  Manivannan Subramaniyan,et al.  Annals of the New York Academy of Sciences Dopaminergic and Cholinergic Learning Mechanisms in Nicotine Addiction , 2022 .

[24]  H. Lester,et al.  Ketamine inside neurons? , 2015, The American journal of psychiatry.

[25]  보웬 아담,et al.  Nicotine salt formulations for aerosol devices and methods thereof , 2014 .

[26]  H. Lester,et al.  Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease. , 2014, Pharmacological research.

[27]  Ethan B. Van Arnam,et al.  Functional Probes of Drug–Receptor Interactions Implicated by Structural Studies: Cys-Loop Receptors Provide a Fertile Testing Ground , 2014, Journal of medicinal chemistry.

[28]  D. A. Dougherty,et al.  An Unusual Pattern of Ligand-Receptor Interactions for the α7 Nicotinic Acetylcholine Receptor, with Implications for the Binding of Varenicline , 2013, Molecular Pharmacology.

[29]  L. Dwoskin,et al.  Potential therapeutic uses of mecamylamine and its stereoisomers , 2013, Pharmacology Biochemistry and Behavior.

[30]  Mark T. Harnett,et al.  An optimized fluorescent probe for visualizing glutamate neurotransmission , 2013, Nature Methods.

[31]  H. Lester,et al.  Psychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects , 2012, Biological Psychiatry.

[32]  E. Levin,et al.  Chronic Sazetidine-A at Behaviorally Active Doses Does Not Increase Nicotinic Cholinergic Receptors in Rodent Brain , 2012, Journal of Pharmacology and Experimental Therapeutics.

[33]  H. Lester,et al.  Variations in binding among several agonists at two stoichiometries of the neuronal, α4β2 nicotinic receptor. , 2012, Journal of the American Chemical Society.

[34]  Teja W. Groemer,et al.  Use-Dependent Inhibition of Synaptic Transmission by the Secretion of Intravesicularly Accumulated Antipsychotic Drugs , 2012, Neuron.

[35]  H. Lester,et al.  Pharmacological Chaperoning of Nicotinic Acetylcholine Receptors Reduces the Endoplasmic Reticulum Stress Response , 2012, Molecular Pharmacology.

[36]  H. Waterbeemd,et al.  Pharmacokinetics and Metabolism in Drug Design: SMITH:PHARMACOKINETICS 3E O-BK , 2012 .

[37]  H. Lester,et al.  Trafficking of alpha4* nicotinic receptors revealed by superecliptic phluorin: effects of a beta4 amyotrophic lateral sclerosis-associated mutation and chronic exposure to nicotine. , 2011, The Journal of biological chemistry.

[38]  E. Bremer,et al.  The crystal structure of the substrate-binding protein OpuBC from Bacillus subtilis in complex with choline. , 2011, Journal of molecular biology.

[39]  H. Gohlke,et al.  Arg149 is involved in switching the low affinity, open state of the binding protein AfProX into its high affinity, closed state. , 2011, Journal of molecular biology.

[40]  Cong-Zhao Zhou,et al.  Structures of the substrate-binding protein provide insights into the multiple compatible solute binding specificities of the Bacillus subtilis ABC transporter OpuC. , 2011, The Biochemical journal.

[41]  E. Snapp,et al.  Superfolder GFP Is Fluorescent in Oxidizing Environments When Targeted via the Sec Translocon , 2011, Traffic.

[42]  H. Lester,et al.  Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses , 2011, Neuron.

[43]  Philip R. Evans,et al.  An introduction to data reduction: space-group determination, scaling and intensity statistics , 2011, Acta crystallographica. Section D, Biological crystallography.

[44]  H. Lester,et al.  Nicotine up-regulates α4β2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning , 2011, The Journal of general physiology.

[45]  Lutz Schmitt,et al.  A structural classification of substrate‐binding proteins , 2010, FEBS letters.

[46]  D. Bertrand,et al.  Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence , 2010, British journal of pharmacology.

[47]  J. C. Wolters,et al.  Ligand Binding and Crystal Structures of the Substrate-Binding Domain of the ABC Transporter OpuA , 2010, PloS one.

[48]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[49]  H. Lester,et al.  GABA transporter function, oligomerization state, and anchoring: correlates with subcellularly resolved FRET , 2009, The Journal of general physiology.

[50]  K. O’Malley,et al.  Intracellular Metabotropic Glutamate Receptor 5 (mGluR5) Activates Signaling Cascades Distinct from Cell Surface Counterparts* , 2009, The Journal of Biological Chemistry.

[51]  P. Vezina,et al.  Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. , 2009, Biochemical pharmacology.

[52]  H. Lester,et al.  Nicotine is a Selective Pharmacological Chaperone of Acetylcholine Receptor Number and Stoichiometry. Implications for Drug Discovery , 2009, The AAPS Journal.

[53]  Erik A. Rodriguez,et al.  Single-molecule imaging of a fluorescent unnatural amino acid incorporated into nicotinic receptors. , 2009, Biophysical journal.

[54]  E. Bremer,et al.  Crystal Structures of the Choline/Acetylcholine Substrate-binding Protein ChoX from Sinorhizobium meliloti in the Liganded and Unliganded-Closed States* , 2008, Journal of Biological Chemistry.

[55]  Johannes Kornhuber,et al.  Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.

[56]  K. Fagerström,et al.  Varenicline in the treatment of tobacco dependence , 2008, Neuropsychiatric disease and treatment.

[57]  R. J. Mather,et al.  Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.

[58]  M. Stolar,et al.  Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers , 2006, Journal of clinical pharmacology.

[59]  F. Ivy Carroll,et al.  Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors , 2006, Molecular Pharmacology.

[60]  A. Kuryatov,et al.  Nicotine Acts as a Pharmacological Chaperone to Up-Regulate Human α4β2 Acetylcholine Receptors , 2005, Molecular Pharmacology.

[61]  J. Daly.  Nicotinic Agonists, Antagonists, and Modulators From Natural Sources , 2005, Cellular and Molecular Neurobiology.

[62]  J. Changeux,et al.  Nicotine Upregulates Its Own Receptors through Enhanced Intracellular Maturation , 2005, Neuron.

[63]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[64]  K. Diederichs,et al.  Structural Basis for the Binding of Compatible Solutes by ProX from the Hyperthermophilic Archaeon Archaeoglobus fulgidus* , 2004, Journal of Biological Chemistry.

[65]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[66]  Kay Diederichs,et al.  Cation-π Interactions as Determinants for Binding of the Compatible Solutes Glycine Betaine and Proline Betaine by the Periplasmic Ligand-binding Protein ProX from Escherichia coli* , 2004, Journal of Biological Chemistry.

[67]  S. Quake,et al.  Number, Density, and Surface/Cytoplasmic Distribution of GABA Transporters at Presynaptic Structures of Knock-In Mice Carrying GABA Transporter Subtype 1–Green Fluorescent Protein Fusions , 2002, The Journal of Neuroscience.

[68]  H. Lester,et al.  A perturbed pK(a) at the binding site of the nicotinic acetylcholine receptor: implications for nicotine binding. , 2002, Journal of the American Chemical Society.

[69]  Niki M Zacharias,et al.  Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. , 2002, Biochemistry.

[70]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[71]  Han van de Waterbeemd,et al.  Pharmacokinetics and metabolism in drug design , 2001 .

[72]  D. A. Dougherty,et al.  From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Köppen,et al.  Uptake and Metabolism of Choline by Rat Brain After Acute Choline Administration , 1992, Journal of neurochemistry.

[74]  N. Benowitz,et al.  Stable isotope studies of nicotine kinetics and bioavailability , 1991, Clinical pharmacology and therapeutics.

[75]  A. C. Collins,et al.  Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. , 1985, The Journal of pharmacology and experimental therapeutics.

[76]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.

[77]  P. Mitchell.  CHEMIOSMOTIC COUPLING IN OXIDATIVE AND PHOTOSYNTHETIC PHOSPHORYLATION , 1966, Biological reviews of the Cambridge Philosophical Society.

[78]  B. Katz,et al.  On the localization of acetylcholine receptors , 1955, The Journal of physiology.

[79]  R. Tyndale,et al.  Pharmacogenetics of nicotine and associated smoking behaviors. , 2015, Current topics in behavioral neurosciences.

[80]  L. Castellano,et al.  Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[81]  Sergio Grinstein,et al.  Sensors and regulators of intracellular pH , 2010, Nature Reviews Molecular Cell Biology.

[82]  T. Terwilliger,et al.  Engineering and characterization of a superfolder green fluorescent protein , 2006, Nature Biotechnology.